USD
+$0.00
(+0.00%
)At Close (As of Sep 17, 2025)
$5.27B
Market Cap
-
P/E Ratio
-0.78
EPS
$21.69
52 Week High
$10.45
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $2.9B |
Total Revenue | $4.8B |
Cost Of Revenue | $1.9B |
Costof Goods And Services Sold | $1.9B |
Operating Income | $162M |
Selling General And Administrative | $1.6B |
Research And Development | $361M |
Operating Expenses | $2.8B |
Investment Income Net | - |
Net Interest Income | -$384M |
Interest Income | $15M |
Interest Expense | $399M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $436M |
Income Before Tax | -$234M |
Income Tax Expense | $71M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$305M |
Comprehensive Income Net Of Tax | - |
Ebit | $178M |
Ebitda | $614M |
Net Income | -$317M |
Field | Value (USD) |
---|---|
Total Assets | $13B |
Total Current Assets | $2.8B |
Cash And Cash Equivalents At Carrying Value | $305M |
Cash And Short Term Investments | $305M |
Inventory | $1B |
Current Net Receivables | $1B |
Total Non Current Assets | $11B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $3.5B |
Intangible Assets Excluding Goodwill | $3.5B |
Goodwill | $4.5B |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $421M |
Other Non Current Assets | - |
Total Liabilities | $6.9B |
Total Current Liabilities | $1.7B |
Current Accounts Payable | $389M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $40M |
Total Non Current Liabilities | $5.2B |
Capital Lease Obligations | - |
Long Term Debt | $4.7B |
Current Long Term Debt | $40M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $4.8B |
Other Current Liabilities | $1.3B |
Other Non Current Liabilities | $430M |
Total Shareholder Equity | $6.5B |
Treasury Stock | - |
Retained Earnings | -$571M |
Common Stock | - |
Common Stock Shares Outstanding | $352M |
Field | Value (USD) |
---|---|
Operating Cashflow | $232M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $436M |
Capital Expenditures | $291M |
Change In Receivables | - |
Change In Inventory | -$147M |
Profit Loss | - |
Cashflow From Investment | -$412M |
Cashflow From Financing | $178M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$12M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$305M |
Field | Value (USD) |
---|---|
Gross Profit | $2.9B |
Total Revenue | $4.8B |
Cost Of Revenue | $1.9B |
Costof Goods And Services Sold | $1.9B |
Operating Income | $162M |
Selling General And Administrative | $1.6B |
Research And Development | $361M |
Operating Expenses | $2.8B |
Investment Income Net | - |
Net Interest Income | -$384M |
Interest Income | $15M |
Interest Expense | $399M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $436M |
Income Before Tax | -$234M |
Income Tax Expense | $71M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$305M |
Comprehensive Income Net Of Tax | - |
Ebit | $178M |
Ebitda | $614M |
Net Income | -$317M |
Sector: HEALTHCARE
Industry: MEDICAL INSTRUMENTS & SUPPLIES
Bausch + Lomb Corporation is a leading global eye health company, headquartered in Vaughan, Canada, specializing in the development and distribution of innovative products for vision health. The company offers a comprehensive portfolio that includes contact lenses, lens care products, surgical solutions, and pharmaceutical offerings aimed at treating ocular conditions. With a strong commitment to research and development, Bausch + Lomb leverages advanced technology to enhance consumer experiences and improve patient outcomes, positioning itself as a trusted partner in the ophthalmic market. Its extensive global reach and dedication to quality solidify Bausch + Lomb’s status as a key player in the eye health sector.